BACKGROUND: In pregnancy-associated malaria (PAM), Plasmodium falciparum-infected erythrocytes (IEs) express variant surface antigens (VSA-PAM) that evade existing immunity and mediate placental sequestration. Antibodies to VSA-PAM develop with gravidity and block placental adhesion or opsonize IEs for phagocytic clearance, helping to prevent maternal anemia and low birth weight in infants. METHODS: Using serum samples from 141 pregnant Malawian women with parasitemia enrolled in a randomized trial of antimalarials and VSA-PAM-expressing CS2 IEs, we quantified levels of immunoglobulin (Ig) G to VSA-PAM by flow cytometry and levels of opsonizing antibodies by measuring uptake of IEs by THP1 promonocytes. RESULTS: After controlling for gravidity and antimalarial treatment, higher levels of IgG to VSA-PAM were associated with decreased anemia at delivery (odds ratio [OR], 0.66 [95% confidence interval {CI}, 0.46-0.93]; P = .018) and were weakly associated with decreased parasitological failure (OR, 0.78 [95% CI, 0.60-1.03]; P = .075), especially reinfection (OR, 0.73 [95% CI, 0.53-1.01]; P = .057). Higher levels of opsonizing antibodies to CS2 IEs were associated with less maternal anemia (OR, 0.31 [95% CI, 0.13-0.74]; P = .008) and treatment failure (OR, 0.48 [95% CI, 0.25-0.90]; P = .023), primarily because of recrudescent infection (OR, 0.49 [95% CI, 0.21-1.12]; P = .089). CONCLUSION: Higher levels of both IgG antibodies to VSA-PAM and opsonizing antibodies, a functional measure of immunity, correlate with parasite clearance and less anemia in pregnancy malaria.
RCT Entities:
BACKGROUND: In pregnancy-associated malaria (PAM), Plasmodium falciparum-infected erythrocytes (IEs) express variant surface antigens (VSA-PAM) that evade existing immunity and mediate placental sequestration. Antibodies to VSA-PAM develop with gravidity and block placental adhesion or opsonize IEs for phagocytic clearance, helping to prevent maternal anemia and low birth weight in infants. METHODS: Using serum samples from 141 pregnant Malawian women with parasitemia enrolled in a randomized trial of antimalarials and VSA-PAM-expressing CS2IEs, we quantified levels of immunoglobulin (Ig) G to VSA-PAM by flow cytometry and levels of opsonizing antibodies by measuring uptake of IEs by THP1 promonocytes. RESULTS: After controlling for gravidity and antimalarial treatment, higher levels of IgG to VSA-PAM were associated with decreased anemia at delivery (odds ratio [OR], 0.66 [95% confidence interval {CI}, 0.46-0.93]; P = .018) and were weakly associated with decreased parasitological failure (OR, 0.78 [95% CI, 0.60-1.03]; P = .075), especially reinfection (OR, 0.73 [95% CI, 0.53-1.01]; P = .057). Higher levels of opsonizing antibodies to CS2IEs were associated with less maternal anemia (OR, 0.31 [95% CI, 0.13-0.74]; P = .008) and treatment failure (OR, 0.48 [95% CI, 0.25-0.90]; P = .023), primarily because of recrudescent infection (OR, 0.49 [95% CI, 0.21-1.12]; P = .089). CONCLUSION: Higher levels of both IgG antibodies to VSA-PAM and opsonizing antibodies, a functional measure of immunity, correlate with parasite clearance and less anemia in pregnancy malaria.
Authors: Salenna R Elliott; Amy K Brennan; James G Beeson; Eyob Tadesse; Malcolm E Molyneux; Graham V Brown; Stephen J Rogerson Journal: Infect Immun Date: 2005-09 Impact factor: 3.441
Authors: Margaret Pinder; Colin J Sutherland; Fatoumatta Sisay-Joof; Jamila Ismaili; Matthew B B McCall; Rosalyn Ord; Rachel Hallett; Anthony A Holder; Paul Milligan Journal: Infect Immun Date: 2006-05 Impact factor: 3.441
Authors: R W Steketee; J J Wirima; P B Bloland; B Chilima; J H Mermin; L Chitsulo; J G Breman Journal: Am J Trop Med Hyg Date: 1996 Impact factor: 2.345
Authors: Lester H Lambert; Jeanee L Bullock; Sharma T Cook; Kazutoyo Miura; David N Garboczi; Mahamadou Diakite; Rick M Fairhurst; Kavita Singh; Carole A Long Journal: Infect Immun Date: 2014-08-25 Impact factor: 3.441
Authors: Anna Babakhanyan; Yeung L Tutterrow; Naveen Bobbili; Ali Salanti; Andrew Wey; Josephine Fogako; Robert J Leke; Rose G F Leke; Diane Wallace Taylor Journal: Am J Trop Med Hyg Date: 2015-12-28 Impact factor: 2.345
Authors: Yukie M Lloyd; Rui Fang; Naveen Bobbili; Koko Vanda; Elise Ngati; Maria J Sanchez-Quintero; Ali Salanti; John J Chen; Rose G F Leke; Diane W Taylor Journal: Infect Immun Date: 2018-08-22 Impact factor: 3.441
Authors: Steve M Taylor; Mwayiwawo Madanitsa; Kyaw-Lay Thwai; Carole Khairallah; Linda Kalilani-Phiri; Anna M van Eijk; Victor Mwapasa; Feiko O Ter Kuile; Steven R Meshnick Journal: J Infect Dis Date: 2017-08-01 Impact factor: 5.226
Authors: Ricardo Ataíde; Wina Hasang; Danny W Wilson; James G Beeson; Victor Mwapasa; Malcolm E Molyneux; Steven R Meshnick; Stephen J Rogerson Journal: PLoS One Date: 2010-05-25 Impact factor: 3.240
Authors: Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin Journal: Immunol Rev Date: 2013-07 Impact factor: 12.988
Authors: Ricardo Ataide; Elizabeth A Ashley; Rosanna Powell; Jo-Anne Chan; Michael J Malloy; Katherine O'Flaherty; Eizo Takashima; Christine Langer; Takafumi Tsuboi; Arjen M Dondorp; Nicholas P Day; Mehul Dhorda; Rick M Fairhurst; Pharath Lim; Chanaki Amaratunga; Sasithon Pukrittayakamee; Tran Tinh Hien; Ye Htut; Mayfong Mayxay; M Abul Faiz; James G Beeson; Francois Nosten; Julie A Simpson; Nicholas J White; Freya J I Fowkes Journal: Proc Natl Acad Sci U S A Date: 2017-03-13 Impact factor: 11.205